Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2013

View Archived Issues

AnaptysBio adds new combination therapies to its immunotherapy portfolio

Galera initiates phase I head and neck cancer trial with new product

Pilocarpine/tolterodine fixed-dose combination is well tolerated at increased total daily doses

Researchers at Allergan disclose novel FPR2/ALX receptor ligands

Millennium Pharmaceuticals prepares new ubiquitin-activating enzyme inhibitors

Fedovapagon tested as potential therapy for nocturia associated with BPH

Teva Pharmaceutical begins phase I CEP-37440 study

Research Triangle Institute discloses novel CB1 receptor antagonists

Meda to acquire Acton Pharmaceuticals

Arizona State University synthesizes new agents for mitochondrial disorders

Researchers at IGM Biosciences patent novel antigen binding proteins

Ophthotech opens enrollment for phase III Fovista program

Subcutaneous Herceptin approved in Europe

Teva will not proceed with Nuvigil regulatory filing in depression following trial results

Debiopharm initiates phase I Debio-1347 trial

Aubagio approved in Europe for relapsing-remitting MS

RaQualia-Interprotein collaboration yields protein-protein interaction inhibitor hits

SBI Pharmaceuticals plans phase II study for chemotherapy-induced anemia

AZD-7507 demonstrates good oral pharmacokinetic profile in vivo

AesRx cleared to begin phase II trial of AES-103 in sickle cell disease

Antihypertensive, cardioprotective activity of intestinal NHE-3 blockade with SAR-218034

The University of Tsukuba presents novel agents for cancer

UCB Canada announces launch of rotigotine patch for patients with Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...